

# EUROPEAN CURRICULUM VITAE FORMAT



## PERSONAL INFORMATION

Name

**CLAUDIA PROTO**

## WORK EXPERIENCE

- Dates (from – to)
- Name and address of employer
- Type of business or sector
- Occupation or position held
- Main activities and responsibilities

### **1 APRIL 2021 - PRESENT**

Fondazione IRCCS – Istituto Nazionale Tumori  
Milan, Italy

Public Hospital

Medical oncologist, permanent contract

Departmental activities, day-hospital and clinical ambulatory

Areas of interest: Medical Thoracic Oncology (lung cancer, pleural mesothelioma, thymic tumors). Diagnostic and therapeutic iter management: diagnosis and staging of disease. Use of chemotherapy, biological agents, immunotherapy and supportive care. Management of clinical and experimental trials. Translational research.

- Dates (from – to)
- Name and address of employer
- Type of business or sector
- Occupation or position held
- Main activities and responsibilities

### **1 JUNE 2019 - 31 MARCH 2021**

Fondazione IRCCS – Istituto Nazionale Tumori  
Milan, Italy

Public Hospital

Medical oncologist, fixed-term contract

Departmental activities, day-hospital and clinical ambulatory

Areas of interest: Medical Thoracic Oncology (lung cancer, pleural mesothelioma, thymic tumors). Diagnostic and therapeutic iter management: diagnosis and staging of disease. Use of chemotherapy, biological agents, immunotherapy and supportive care. Management of clinical and experimental trials. Translational research.

- Dates (from – to)
- Name and address of employer
- Type of business or sector
- Occupation or position held
- Main activities and responsibilities

### **21 NOVEMBER 2014 – 31 MAY 2019**

Fondazione IRCCS – Istituto Nazionale Tumori  
Milan, Italy

Public Hospital

Professional Scientific Collaborator – Consultant Oncologist

Departmental activities, day-hospital and clinical ambulatory

Areas of interest: Medical Thoracic Oncology (lung cancer, pleural mesothelioma, thymic tumors). Diagnostic and therapeutic iter management: diagnosis and staging of disease. Use of chemotherapy, biological agents, immunotherapy and supportive care. Management of clinical and experimental trials. Translational research.

- Dates (from – to)
- Name and address of employer

### **30 JUNE 2009 – 30 JUNE 2014**

Residency Program in Medical Oncology - University of Messina c / o Policlinico "G. Martino"  
and AOOR Papardo-Piedmont e- UOC Medical Oncology, Director Prof. V. Adamo - Messina.

- Type of business or sector
- Occupation or position held
- Main activities and responsibilities

Public Hospital

Resident in medical oncology

Internal Medicine for 7 months. Inpatients care, outpatients care and day hospital in Medical Oncology. Periods of training in: Molecular Biology (DNA and RNA extraction and sequencing, RT-PCR, cell culture), Pathology (macroscopic and microscopic examination of surgical specimens, immunohistochemistry, FISH), radiology (ultrasound, mammography, CT, MRI), radiotherapy, General Surgery, Anaesthesia.

Areas of interest: lung tumors, tumors of the head and neck, tumors of the central nervous system, breast cancer, gynecological cancers and melanomas. Experience in the use of chemotherapy and biological agents, supportive care, clinical trials and translational research.

Final thesis: "Integrated therapeutic approach and biomolecular characterization in the treatment of squamous cell carcinoma of head and neck: experience of three metropolitan areas".

- Title of qualification awarded
- Level in national classification

Medical Oncologist

50/50 cum laude

- Dates (from – to)

- Name and address of employer

**JULY 2009 –NOVEMBER 2014**

National Health System – ASP 5, Messina

- Type of business or sector
- Occupation or position held

Public

Substitute doctor in continuity of care structures

- Dates (from – to)

- Name and address of employer

- Type of business or sector
- Occupation or position held

**JULY 2009 – NOVEMBER 2014**

General Practitioner, Dott. Umberto Mammola, via Placida n°84, Messina

Private

Substitute General Practitioner

## EDUCATION AND TRAINING

- Dates (from – to)

- Name and type of organisation providing education and training

- Title of qualification awarded

- Level in national classification

**FEBRUARY 2009**

University of Messina – Faculty of Medicine and Surgery

Qualification to practice the profession of Medical Doctor (MD), enrolled to 'Order of Physicians and Surgeons' of the Province of Messina

270/270

- Dates (from – to)

- Name and type of organisation providing education and training

- Principal subjects/occupational skills covered

- Title of qualification awarded

**JANUARY 2005 – OCTOBER 2008**

University of Messina - AOU Policlinico "G. Martino ", UOC Integrated Therapies in Oncology, Dir. Prof. Vincenzo Adamo

Prevention, diagnosis, staging and medical (adjuvant, neoadjuvant, and metastatic) treatment for malignant neoplasms; research and clinical trials; supportive care and management of terminal patients.

Training in Medical Oncology

- Dates (from – to)

- Name and type of organisation providing education and training

- Occupation or position held

- Principal subjects/occupational skills covered

**OCTOBER 2002 – OCTOBER 2008**

University of Messina – Faculty of Medicine and Surgery

Medical student

Biology and genetics, anatomy, physiology, pathophysiology of human diseases, pathology, diagnostic imaging and radiation therapy, pharmacology, clinical oncology and hematology,

- Title of qualification awarded
- Level in national classification

general surgery, internal medicine

Thesis in Oncology: "The role of molecular targeted therapy in the treatment of advanced lung cancer NSC. Our experience with erlotinib".

Medical Doctor (MD)

110/110 cum laude

- Dates (from – to)

- Name and type of organisation providing education and training

- Occupation or position held

- Principal subjects/occupational skills covered

- Title of qualification awarded

- Level in national classification

**1997/1998 – 2000/2001**

Liceo Classico "Vittorio Emanuele", Patti (ME)

Student

Italian, English, Latin, Greek, Biology, Mathematics, Physics, History, Philosophy

High school degree

100/100

- Dates (from – to)

- Name and type of organisation providing education and training

2010

Trinity College – London

- Title of qualification awarded

**Certificate of Spoken English for Speakers of Other Languages**

## PERSONAL SKILLS AND COMPETENCES

MOTHER TONGUE

**ITALIAN**

OTHER LANGUAGES

## ENGLISH

- Reading skills

EXCELLENT

- Writing skills

EXCELLENT

- Verbal skills

EXCELLENT

## ORGANISATIONAL SKILLS AND COMPETENCES

Excellent interpersonal and teamwork skills.

Management of clinical trial (Phase I, II and III)

Competence in clinical activities and in relationships with the patients

Realization of research projects

**(EXPERIENCE AS PRINCIPAL-INVESTIGATOR IN ABOUT 30 CLINICAL TRIALS FOCUSING ON THORACIC TUMORS)**

## TECHNICAL SKILLS AND COMPETENCES

Excellent ability to use PC (Word, Power Point, Outlook, Internet, Excel) and to research in public databases

BLSD and ADVANCED LIFE SUPPORT

## GRANTS

Bando per la Ricerca Istituzionale (BRI) 2021 as PI of the research project entitled "Circulating

microRNAs to choose the IO strategy in PD-L1  $\geq 50\%$  NSCLC patients: the Ark clinical trial “.

Bando per la Ricerca Finalizzata 2019 as co-PI of the research project entitled “*Exosomal-PD-L1 as determinant of treatment with immunecheckpoints inhibitors in advanced NSCLC*”

Bando per la Ricerca Finalizzata 2016 as co-PI of the research project entitled “Altered hedgehog pathway in malignant pleural mesothelioma as source for new prognostic biomarkers and therapeutic targets”

SCIENTIFIC AFFILIATIONS

ITALIAN ASSOCIATION OF MEDICAL ONCOLOGY – AIOM  
EUROPEAN SOCIETY OF MEDICAL ONCOLOGY - ESMO

DRIVING LICENSE

B driving license

**Abstract:**

1. Picone A, Franchina T, Russo A, **Proto C**, Raiti F, Buda C, Chiofalo G, Ferraro G, Picciotto M, Scimone A, Toscano G, Zanghi M, Adamo V. Impact of EGFR tyrosine kinase inhibitors in the management of brain metastases from EGFR-mutated and wild-type (WT) non-small cell lung cancer (NSCLC): A survival analysis. J Clin Oncol 32, 2014 (suppl; abstr e19164), ASCO 2014
2. Chiofalo G, Toscano G, Berenato R, Smirolto V, Noto L, **Proto C**, Buda C, Giuffrè G, Adamo V. Correlation between biological agent based regimens as first-line treatment and outcomes in patients with Kras wild type metastatic colorectal cancer (mCRC). Suppl Tumori 2013; S25 (abstr. A49).
3. Ferraro G, **Proto C**, Del re C, Agostino R, Zanghi M, Buda C, Ricciardi GRR; Adamo V. Correlation between serum magnesium levels and skin toxicity during cetuximab treatment squamous cell carcinoma of head and neck cancer (SCCHN): the role of weekly intravenous magnesium supplementation. Suppl Tumori 2013. S33-34 (abstr B15)
4. Franchina T, Bronte G, Savio G, Ferraro G, **Proto C**, Berenato R, Noto L, Chiofalo G, Russo A, Adamo V. New biomarkers to predict response to pemetrexed-based chemotherapy in non small cell lung cancer: from 5,10-methylenetetrahydrofolate reductase promises to miRNAs revolution. Suppl Tumori 2012; 13 (3):S85-86 (abstr D23). *XIVA IOM*
5. Franchina T, Amodeo V, **Proto C**, Bronte G, Savio G, Russo A, Toscano G, Russo A, Adamo V. Impact of circulating microRNAs mir-22, mir-24 and mir-34a on response to pemetrexed in patients with non small cell lung cancer. *Poster alla III CIOT 2012*
6. Caristi N, Franchina T, **Proto C**, Chiofalo G, Toscano G, Scimone A, Zanghi M, Berenato R, Briguglio R, Denaro N, Noto L, Adamo V. Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience. J Clin Oncol. 2011; 29 (suppl; abstr e18063)
7. Franchina T, Caristi N, **Proto C**, Chiofalo G, Toscano G, Ricciardi G, Colonese F, Caccamo D, Ientile R, Adamo V. Folate pathway implications in advanced Non Small Cell Lung Cancer (NSCLC): impact of thymidylate synthase (TS) promoter and methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C variants expression on patients' outcome and correlation with p53 codon 72 mutations. J Thorac Oncol. 2011; 6(6, suppl 2) abstract P2.054. S955. *Poster 14th WCLC IASLC*
8. Franchina T, **Proto C**, Noto L, Chiofalo G, Ferraro G, Picciotto M, Adamo V. Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: a case report. Suppl Tumori 2011; 11 (2):S83 (abstr. D67).
9. Franchina T, Scimone A, Ferraro G, Garipoli C, Zanghi M, Berenato R, Briguglio R, Noto L, **Proto C**, Adamo V. Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors? Suppl Tumori 2010; 10 (1):S74-75 (abstr D43) *Poster XII A IOM*
10. **Proto C**, Lo Russo G, Macerelli M, Vitali M, Agustoni F, Platania M, Zilembo N, Ganzinelli M, Tiseo M, Pasello G, Gallucci R, Cona MS, Botta L, Trama A, de Braud F, Garassino MC, Signorelli D. Lume Trial: searching for survival prognostic factors in malignant pleural mesothelioma. Ann Oncol 2015 26 (6).
11. Lo Russo G, Macerelli M, **Proto C**, Vitali M, Signorelli D, Gallucci R, Platania M, Agustoni F, Zilembo N, Ganzinelli M, Raimondi A, Trama A, de Braud F, Garassino MC. Absence of standard in the management of Thimic Epithelial Tumors. Ann Oncol 2015 26 (6).
12. Signorelli D, Cona MS, Lo Russo G, **Proto C**, Vitali M, Macerelli M, Agustoni F, Indini A, Platania M, Zilembo N, Garassino MC, Di Guardo L, Del Vecchio M, Magni M, Sinno V, Seregini E, Di Nicola M, de Braud F. Disthyroidism during immune checkpoints inhibitors treatment: toxicity or something more? Ann Oncol 2015 26 (6).
13. Signorelli D, **Proto C**, Ganzinelli M, Lo Russo G, Botta L, Trama A, Pasello G, Tiseo M, Pelosi G, Garassino M. SMO mutation is a strong negative prognostic factor in malignant pleural mesothelioma. J Thorac Oncol 2016 11 (4): S57-S166. S1556-0864(16)X0004-4. *Poster ELCC 2016 (SU PUBMED)*
14. Agustoni F, Fucà G, Corrao G, Vernieri C, Cavalieri S, Raimondi A, Peverelli G, Prisciandaro M, Indelicato P, Dotti K, Morano F, Lo Russo G, Signorelli D, **Proto C**, Vitali M, Imbimbo M, Zilembo N, Garassino M, De Braud F, Platania M. 1469P - Impact of hyponatremia in a tertiary cancer center: A one-year-survey at National Cancer Institute of Milan. Abstract ESMO 2016.

15. Agostoni F, Fucà G, Corrao G, Vernieri C, Cavalieri S, Raimondi A, Peverelli G, Prisciandaro M, Indelicato P, Lo Russo G, Signorelli D, **Proto C**, Vitali M, Imbimbo M, Zilembo N, Garassino M, Procopio G, De Braud F, Morelli D, Platania M. Impact of hyponatremia in a tertiary cancer center: A one-year-survey at National Cancer Institute of Milan. Poster AIOM 2016
16. **Proto C**, Ganzinelli M, Botta L, Tiseo M, Pasello G, Fabbri A, Lo Russo G, Trama A, Imbimbo M, Vitali M, Macerelli M, Zilembo N, Gallucci R, Brissa A, Platania M, Zaffaroni N, Serafini MS, de Braud F, Garassino MC, Signorelli D. SMO mutations role in Malignant Pleural Mesothelioma: a negative prognostic factor, but possible new target? Poster AIOM 2016 (Premio Berlucchi)
17. **Proto C**, Signorelli D, Mallone S, Greco FG, Calareso G, Botta L, Lo Russo G, Imbimbo M, Vitali M, Ganzinelli M, Zilembo N, Platania M, Pastorino U, Garassino MC, Trama A. Study comparing volume and TNM in predicting clinical outcome in Malignant Pleural Mesothelioma. Abstract WCLC 2016.
18. Trama A, Botta L, Signorelli D, **Proto C**, Gennaro V, Benfatto L, Lando CF, Mensi C, Dallari B, Consonni D, Merler E, Bressan V, Mirabelli D, Gangemi M, Brentisci C, Stura A, Romanelli A, Storch C, Chellini E, Cocchioni M, Pascucci C, La Rosa F, Petrucci MS, Ascoli V, Angelillo IF, Feola D, Tumino R, Tagliabue G, Contiero P, Gola G, Corti M, Fanetti AC, Crocetti E, Caldarella A, Sciacca S, Bella F, Cusimano R, Amodio R, Ziino A, Candela P, Scuderi T, Frasca G, Giuridanella MC, Cirilli C, Michiara M, Rimanti A, Tiseo M, De Giorgi AM, Sgargi P, Mangone L, Vicentini M, Falcini F, Giuliani O, Vattiato R, Fusco M, Vitale MF, Piffer S, Rizzello RV, Piro R, Forastiere F, Romeo E, De Angelis R, Capocaccia R, Mallone S, Foschi R, Gatta G, Garassino MC. Malignant pleural mesothelioma long-term survivors: a population based study (LUME study). iMig 2016
19. Botta L, Trama A, **Proto C**, Signorelli D, Garassino MC, Capocaccia R, Gatta G. Malignant pleural mesothelioma long-term survivors: a population based study (LUME study). GRELL 2016
20. D Cortinovis, A Delmonte, R Chiari, A Catino, F Grossi, C Noverasco, F Gelsomino, M Gilli, **C Proto**, H Soto Parra, M R Migliorino, L Bonomi, D Tassinari, A Frassoldati, V Albanese, G Fadda, F De Galitiis, G Finocchiaro, F Cognetti. Italian Nivolumab Advanced Squamous NSCLC Expanded Access Program: Efficacy and Safety in Patients with Brain Metastases. P3.02c-094. JTO Volume 12, Issue 1, Supplement, January 2017, Page S1336
21. Signorelli D, Cona MS, Vitali M, Lo Russo G, **Proto C**, Imbimbo M, Zilembo N, Platania M, Del Vecchio M, Seregni M, Garassino MC, Di Nicola MA, De Braud FG. Correlation between dysthyroidism and efficacy in patients treated with anti PD-1 or anti PDL-1 agents. Meeting 2017 ASCO-SITC Clinical Immuno-Oncology Symposium. Citation: J Clin Oncol 35, 2017 (suppl 7S; abstract 67)
22. Imbimbo M, **Proto C**, Mallone S, Signorelli S, Greco FG, Calareso G, Botta L, Lo Russo G, Vitali M, Corrao G, Galli G, Ganzinelli M, Zilembo N, Pastorino U, Garassino MC, Trama A. TNM or tumor volume for predicting prognosis in malignant pleural mesothelioma: still an open debate. IASLC WCLC 2017. Yokohama, Japan 15-18/10/2017.
23. Galli G, Lo Russo G, **Proto C**, Signorelli D, Vitali M, Botta L, Imbimbo M, Zilembo N, Garassino M. Potential synergy of immunotherapy and radiotherapy in patients with metastatic non small cell lung cancer: a single Institution experience." [Accepted as Poster at IASLC Immunotherapy 2018 on 27/03/2018].
24. Galli G, Poggi M, Fucà G, Imbimbo M, **Proto C**, Signorelli D, Vitali M, Zilembo N, Ganzinelli M, de Braud F, Garassino M, Lo Russo G. Impact of antibiotics on outcome of metastatic non small cell lung cancer patients treated with immunotherapy." [Mini Oral Presentation at WCLC 2018].
25. G. Sozzi, M. Sommariva, M. Moro, **C. Proto**, D. Signorelli, M. Ganzinelli, S. Sangaletti, M. Boeri, G. Lo Russo, S. Ferro, E. Tassi, V. Huber, L. Sfondrini, M. Milione, C. Tripodo, M. Colombo, A. Anichini, A. Balsari, L. Rivoltini, M. Garassino. PD-1 blockade promotes hyperprogressive disease in NSCLC through macrophages activation via antibody Fc/FcR interaction. [Mini Oral Presentation at WCLC 2018].
26. G. Fucà, M. Poggi, G. Galli, M. Imbimbo, G. Lo Russo, **C. Proto**, M. Vitali, M. Ganzinelli, N. Zilembo, F. De Braud, M. Garassino, D. Signorelli. Effect of early steroids use in advanced NSCLC patients treated with immunotherapy. [Mini Oral Presentation at WCLC 2018].
27. M. Boeri, M. Milione, D. Signorelli, C. **Proto**, G. Lo Russo, C. Galeone, G. Centonze, U. Pastorino, M. Garassino, G. Sozzi. MicroRNA-based liquid biopsy combines with PD-L1 tumor expression to predict response to immunotherapy in advanced NSCLC

- patients. [Mini Oral Presentation at WCLC 2018].
28. Galli G, Poggi M, Fucà G, Imbimbo M, Lo Russo G, **Proto C**, Signorelli D, Ganzinelli M, Zilembo N, de Braud F, Garassino M, Vitali M. Effect of basal lymphopenia on outcome of non small cell lung cancer patients treated with immunotherapy." [Poster at WCLC 2018].
  29. Galli G, Poggi M, Fucà G, Lo Russo G, **Proto C**, Signorelli D, Vitali M, Ganzinelli M, Zilembo N, Filippo de Braud F, Garassino MC, Imbimbo M. Basal lymphopenia as a potential predictor of benefit from immunotherapy in metastatic non small cell lung cancer. ESMO 2018 Congress, 19-23 October, Munich, Germany.
  30. Galli G, Poggi M, Fucà G, Imbimbo M, **Proto C**, Signorelli D, Vitali M, Ganzinelli M, Zilembo N, Filippo de Braud F, Garassino MC, Lo Russo G. Effects of antibiotic use during immunotherapy in metastatic non small cell lung cancer . POSTER 3033. ESMO 2018 Congress, 19-23 October, Munich, Germany.
  31. G Fucà M Poggi G Galli M Imbimbo G Lo Russo D Signorelli M Vitali M Ganzinelli N Zilembo F de Braud M C Garassino **C Proto**. Impact of early steroids use on clinical outcomes of patients with advanced NSCLC treated with immune checkpoint inhibitors. POSTER 1389P. ESMO 2018 Congress, 19-23 October, Munich, Germany. Ann Oncol; 29: 8.
  32. Galli G, Botta L, Poggi M, Fuca' G, Imbimbo M, Lo Russo G, **Proto C**, Vitali M, Zilembo N, Ganzinelli M, de Braud F, Garassino MC., Signorelli D. Concomitant immunotherapy and radiotherapy for metastatic non small cell lung cancer: a single Institution experience. POSTER AIOM 2018
  33. G Fucà, M Poggi, G Galli, M Imbimbo, G Lo Russo, **C Proto**, D Signorelli, M Ganzinelli, N Zilembo, F de Braud, M C Garassino, Vitali F. Prognostic and predictive role of Hyponatremia in patients with metastatic non small cell lung cancer treated with immunotherapy. POSTER AIOM 2018
  34. Galli G, **Proto C**, Signorelli D, Imbimbo M, Ferrara R, Prelaj A, De Toma A, Randon G, Trevisan B, Ganzinelli M, Ganzinelli M, Garassino MC, Lo Russo G. Characterization of patients with metastatic Non Small Cell Lung Cancer obtaining Long Term Benefit from Immunotherapy. ELCC 2019.
  35. Prelaj A, **Lo Russo G**, Signorelli D, Ferrara R, Imbimbo M, Galli G, De Toma A, Randon G, Brambilla M, Trevisan B, Ganzinelli M, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Proto C. EPSiLoN score: validation color of a prognostic score in advanced non-small cell lung cancer (AnscLC) patients treated with immunotherapy. ELCC 2019
  36. Signorelli D, Ferrara R, **Proto C**, Lo Russo G, Imbimbo M, Galli G, De Toma A, Pagani F, Randon G, Fucà G, Trevisan B, Ganzinelli M, Zilembo N, Fabbri A, De Braud F, Garassino MC, Prelaj A. Immune-checkpoints inhibitors in metastatic non small cell lung cancer with rare histology. Abstract 9106 (270539) (Accepted as poster at ASCO 2019)
  37. **C. Proto**, A. Prelaj, C. Verri, D. Signorelli, G. Lo Russo, R. Ferrara, G. Galli, B. Trevisan, M. Mavis, F. G. De Braud, MC. Garassino, G. Sozzi, M. Boeri. A plasma miRNA signature classifier identifies PD-L1  $\geq 50\%$  NSCLC nonresponders to immune checkpoint inhibitors. (Accepted as poster at ASCO 2019)
  38. Galli G, Corsetto PA, Ferrara R, Prelaj A, **Proto C**, Signorelli D, Zilembo N, De Toma A, Pagani F, Randon G, Ganzinelli M, Sica A, de Braud F, Garassino MC, Lo Russo G. Impact of cholesterolemia and body mass index on outcome of metastatic non small cell lung cancer treated with immunotherapy. (Accepted as ABSTRACT at ASCO 2019)
  39. Prelaj A, Lo Russo G, **Proto C**, Signorelli D, Ferrara R, Galli G, De Toma A, Randon G, Zilembo N, Trevisan B, Montrone M, Longo V, Pesola F, Varesano N, Del Bene G, Pizzutillo P, Galetta D, Garassino MC, Di Maio M, Catino AM. Prognostic score for second or further line immunotherapy in advanced non-small cell lung cancer (aNSCLC): An external validation. (Accepted as ABSTRACT at ASCO 2019)
  40. G. Lo Russo, D. Signorelli, **C. Proto**, G. Galli, A. Prelaj, R. Ferrara, M. Sommariva, M. Moro, V. Cancila, M. Ganzinelli, S. Brich, S. Sangaletti, G. Pruneri, C. Tripodo, M.P. Colombo, L. Rivoltini, A. Balsari, G. Sozzi, M. Boeri, M. Garassino. OA14.06 HYPERPROGRESSIVE DISEASE IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS. (Oral presentation WCLC 2019 Barcellona)
  41. Prelaj, **C. Proto**, G. Lo Russo, D. Signorelli, R. Ferrara, M. Mensah, G. Galli, A. De Toma, G. Randon, F. Pagani, M. Brambilla, B. Trevisan, M. Ganzinelli, N. Zilembo, F. De Braud, V. Torri, M. Garassino, G. Sozzi, M. Boeri. MA03.10 PROSPECTIVE

EVALUATION OF A PROGNOSTIC CLINICO-MOLECULAR SCORE (DEMO) TO PREDICT OUTCOME OF ADVANCED NSCLC PATIENTS TREATED WITH IMMUNOTHERAPY. (Minioral WCLC 2019 Barcellona)

42. **Proto C**, Prelaj A, Verri C, Signorelli D, Lo Russo G, Ferrara R, Galli G, Trevisan B, Mavis M., De Braud FG, Garassino MC, Sozzi G, Boeri M. A plasma microRNA classifier as biomarker of primary and secondary resistance in PD-L1 $\geq$ 50% NSCLC treated with immunotherapy Barcelona, 07-10/09/19 WCLC 2019 Mini oral presentation.
43. G. Randon, G. Galli, A. De Toma, F. Pagani, B. Trevisan, D. Signorelli, **C. Proto**, A. Prelaj, R. Ferrara, M. Ganzinelli, L. Pallavicini, R. Di Mauro, N. Zilembo, F. De Braud, M. Garassino, G. Lo Russo. P1.01-135 SALVAGE CHEMOTHERAPY AFTER IMMUNOTHERAPY FAILURE IN NON-SMALL-CELL LUNG CANCER PATIENTS. (Poster WCLC 2019 Barcellona)
44. G. Galli, A. De Toma, F. Pagani, G. Randon, B. Trevisan, A. Prelaj, R. Ferrara, **C. Proto**, D. Signorelli, M. Ganzinelli, N. Zilembo, F. De Braud, M. Garassino, G. Lo Russo. P1.04-38 EFFICACY AND SAFETY OF IMMUNOTHERAPY IN ELDERLY PATIENTS WITH NON-SMALL CELL LUNG CANCER. (Poster WCLC 2019 Barcellona)
45. G. Galli, M. Imbimbo, A. Busico, F. Perrone, E. Tamborini, A. Fabbri, G. Marano, D. Biganzoli, R. Ferrara, G. Lo Russo, A. Prelaj, **C. Proto**, N. Zilembo, A. De Toma, F. Pagani, G. Randon, M. Ganzinelli, E. Biganzoli, G. Pruneri, F. De Braud, M. Garassino, D. Signorelli. P2.09-05 CLINICAL AND BIOLOGICAL CHARACTERIZATION OF LUNG ENTERIC ADENOCARCINOMA. (Poster WCLC 2019 Barcellona)
46. G. Galli, A. Fabbri, R. Ferrara, A. Prelaj, **C. Proto**, D. Signorelli, A. De Toma, F. Pagani, N. Zilembo, M. Ganzinelli, G. Pruneri, F.G.M. de Braud, M.C. Garassino, G. Lo Russo. Accuracy of pathologic evaluation for thymic epithelial tumors in an Italian reference centre. Poster 1855 ESMO 2019
47. Prelaj, **C. Proto**, G. Lo Russo, D. Signorelli, R. Ferrara, G. Galli, A. De Toma, G. Randon, F. Pagani, B. Travisan, M. Ganzinelli, N. Zilembo, F.G.M. De Braud, M. Mensah, V. Torri, M.C. Garassino, G. Sozzi, M. Boeri. 112P DEMo: A prospective evaluation of a prognostic clinico-molecular composite score in NSCLC patients treated with immunotherapy. Poster ESMO 2019
48. G. Galli, R. Ferrara, F. Pagani, A. De Toma, G. Lo Russo, D. Signorelli, A. Prelaj, N. Zilembo, M. Ganzinelli, S. Brich, A. Fabbri, S. Sangaletti, G. Pruneri, M.P. Colombo, F.G.M. de Braud, M.C. Garassino, **C. Proto**. 1992P Prognostic role of CD73 in metastatic non small cell lung cancer according to the presence of driver alterations. Poster ESMO 2019.
49. Randon G., De Toma A., Pagani F., Trevisan B., Prelaj A., Ferrara R., **Proto C.**, Signorelli D., Ganzinelli M., Zilembo N., De Braud F., Garassino M.C., Lo Russo G., Galli G. IMMUNE CHECKPOINT INHIBITORS IN THE ELDERLY WITH NON-SMALL CELL LUNG CANCER: EFFICACY AND SAFETY. POSTER AIOM 2019
50. **Proto C.**, Prelaj A., Verri C., Signorelli D., Lo Russo G., Ferrara R., Galli G., Trevisan B., Mavis M., De Braud F., Garassino M.C., Sozzi G., Boeri M. USING PLASMA MICRORNAS AS BIOMARKERS OF RESISTANCE TO IMMUNE CHECKPOINT INHIBITORS IN PD-L1  $\geq$ 50% ADVANCED NSCLC. POSTER AIOM 2019
51. Ferrara R., Galli G., Pagani F., De Toma A., Lo Russo G., Signorelli D., Prelaj A., Zilembo N., Ganzinelli M., Brich S., Fabbri A., Sangaletti S., Pruneri G., Colombo M.P., De Braud F., Garassino M.C., **Proto C.** PROGNOSTIC ROLE OF CD73 IN METASTATIC NON-SMALL CELL LUNG CANCER ACCORDING TO THE PRESENCE OF DRIVER ALTERATIONS. POSTER AIOM 2019
52. Lo Russo G., Signorelli D., **Proto C.**, Galli G., Prelaj A., Ferrara R., Sommariva M., Moro M., Cancila V., Ganzinelli M., Brich S., Sangaletti S., Boeri M., Pruneri G., Tripodo C., Colombo M.P., Rivoltini L., Balsari A., Sozzi G., Garassino M.C. HYPERPROGRESSIVE DISEASE IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH IMMUNOTHERAPY. POSTER AIOM 2019
53. De Toma A., Lo Russo G., **Proto C.**, Signorelli D., Ferrara R., Prelaj A., Galli G., Pagani F., Trevisan B., Zilembo N., Ganzinelli M., De Braud F., Garassino M.C. INFLUENZA VACCINE IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS (ICis): A SINGLE INSTITUTION EXPERIENCE. POSTER AIOM 2019
54. Pagani F., De Toma A., Randon G., Signorelli D., Lo Russo G., **Proto C.**, Prelaj A., Galli G., Zilembo N., Ganzinelli M., Sangaletti S., Colombo M.P., Campochiaro C., Sica A., De Luca G., Broggin M., Trevisan B., De Braud F., Garassino M.C., Ferrara R.

CYCLOOXYGENASE (COX) INHIBITION IMPACTS THE EFFICACY OF FIRST LINE SINGLE AGENT PD-1/PD-L1 INHIBITORS (ICI) IN ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) PATIENTS (pts). POSTER AIOM 2019

55. Signorelli D., Brambilla M., Ferrara R., **Proto C.**, Lo Russo G., Imbimbo M., Galli G., Pagani F., De Toma A., Fuca' G., Randon G., Trevisan B., Ganzinelli M., Zilembo N., Fabbri A., De Braud F., Garassino M.C., Prelaj A. IMMUNE-CHECKPOINTS INHIBITORS IN ADVANCED NON SMALL CELL LUNG CANCER WITH UNCOMMON HISTOLOGIES. POSTER AIOM 2019
56. Galli G., Fabbri A., Ferrara R., Prelaj A., **Proto C.**, Signorelli D., De Toma A., Pagani F., Zilembo N., Ganzinelli M., Abate-Daga L., Pruneri G., De Braud F., Garassino M.C., Lo Russo G. ACCURACY OF PATHOLOGIC DIAGNOSIS OF THYMIC EPITHELIAL TUMORS: A SINGLE INSTITUTION EXPERIENCE. POSTER AIOM 2019
57. Imbimbo M., Galli G., Busico A., Perrone F., Tamborini E., Fabbri A., Marano G., Biganzoli D., Ferrara R., **Lo Russo G.**, Prelaj A., **Proto C.**, Zilembo N., De Toma A., Ganzinelli M., Biganzoli E., Pruneri G., De Braud F., Garassino M.C., Signorelli D. CLINICAL CHARACTERISTICS AND BIOLOGICAL PROFILE OF LUNG ENTERIC ADENOCARCINOMA. POSTER AIOM 2019
58. Lobefaro R, Viscardi D, Di Liello R, Massa G, Iacovino ML, Sparano F, Ferrara R, Signorelli D, **Proto C**, Prelaj A, Galli G, De Toma A, Brambilla M, Ganzinelli M, Trevisan B, Bottiglieri A, De Braud F, Morgillo F, Garassino MC, Lo Russo G. Efficacy and safety of immunotherapy in non-small cell lung cancer patients with poor performance status. ASCO 2020 Abstract
59. Colombo E, Manca P, Bini M, Bottiglieri A, Massa G, Prinzi N, Torchio M, Niger M, Corti F, Prisciandaro M, Zattarin E, **Proto C**, Garassino MC, Milione M, Cattaneo L, Di Bartolomeo M, Platania M., De Braud FG, Lo Russo G, Pusceddu S. Combined use of albumin and neutrophil-to-lymphocyte ratio as new prognostic and predictive factor in patients with poorly differentiated neuroendocrine carcinomas. ASCO 2020 Abstract
60. Ferrara R, Facchinetti F, Calareso G, Kasraoui I, Signorelli D, **Proto C**, Prelaj A, Naltet C, Lavaud P, Desmaris R, Viscardi G, Galli G, De Toma A, Martinetti A, Barlesi F, Planchard D, Soria JC, Garassino MC, Besse B, Lo Russo G. Hyperprogressive disease upon first-line PD-1/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts). Ann Oncol 2020; 31(Suppl 4):S826.
61. Prelaj A, Bottiglieri A, **Proto C**, Lo Russo G, Signorelli D, Ferrara R, Galli G, De Toma A, Viscardi G, Brambilla M, Lobefaro R, Manglaviti S, Occhipinti M, Labianca A, Gallucci R, Molino G, Zilembo N, Greco FG, Torri V, Garassino MC. Pozitininib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: results from the Expanded Access Program. Ann Oncol 2020; 31(Suppl 4):S882).
62. Brambilla M, Nichetti F, Lobefaro R, Galli G, De Toma A, Viscardi G, Prelaj A, Ferrara R, **Proto C**, Signorelli D, Bottiglieri A, Massa G, Trevisan B, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G. Chemotherapy followed by immunotherapy compared to reverse sequence in NSCLC with PD-L1 low expression: PFS2 analysis. Ann Oncol 2020; 31(Suppl 4):S848.
63. Lobefaro R, Viscardi G, Di Liello R, Massa G, Iacovino ML, Sparano F, Della Corte CM, Ferrara R, Signorelli D, **Proto C**, Prelaj A, Galli G, De Toma A, Brambilla M, Ganzinelli M, Trevisan B, de Braud F, Morgillo F, Garassino MC, Lo Russo G. Immune checkpoint inhibitors in advanced NSCLC patients with poor performance status: The role of clinical/pathological variables and inflammatory biomarkers in a real world experience. Ann Oncol 2020; 31(Suppl 4):S856-S857.
64. Ferrara R, Lo Russo G, Signorelli D, **Proto C**, Prelaj A, Galli G, De Toma A, Viscardi G, Lobefaro R, Brambilla M, Talarico G, Bassani B, Spanò SM, Molino G, Zilembo N, Ganzinelli M, Vitale S, Colombo MP, Garassino MC, Sangaletti S. Circulating and tumor-associated neutrophil subtypes discriminate hyperprogressive disease (HPD) from conventional progression (PD) upon immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients (pts) and in vivo models. J Clin Oncol 2020; 37(Suppl 15):9547.
65. Ferrara R, **Proto C**, Lo Russo G, Signorelli D, Prelaj A, Galli G, Zilembo N, De Toma A, Viscardi G, Lobefaro R, Brambilla M, Ganzinelli M, Molino G, Talarico G, Garassino MC, Colombo MP, Sangaletti S. Circulating and tumor associated neutrophil subtypes correlate with hyperprogressive disease (HPD) upon immunecheckpoint inhibitors (ICI) in advanced non-small cell lung cancer (aNSCLC) patients (pts) and in vivo models. Cancer Res 2020; 80(Suppl 16):4480.
66. Galli G, Fabbri A, Ferrara R, Prelaj A, **Proto C**, Signorelli D, De Toma A, Pagani F, Zilembo N, Ganzinelli M, Abate-Daga L, Pruneri G, de Braud F, Garassino M, Lo

- Russo G. Accuracy of pathologic diagnosis of thymic epithelial tumors: a single Institution experience. *Tumori J* 2019; 106(6S):107.
67. Prelaj A, Boeri M, Robuschi A, **Proto C**, Lo Russo G, Ferrara R, Galli G, De Toma A, Brambilla M, Occhipinti M, Manglaviti S, Labianca A, Beninato T, Bini M, Mensah M, Ganzinelli M, Zilembo N, de Braud F, Sozzi G, Restelli M, Pedrocchi A, Garassino MC, Trovo' F. Artificial Intelligence to improve selection for NSCLC patients treated with immunotherapy POSTER AACR Virtual Special Conference: Artificial Intelligence, Diagnosis, and Imaging

#### **Papers:**

- Urtecho SB, Provenzano L, Spagnoletti A, Bottiglieri A, Pircher C, Massa G, Sposetti C, **Proto C**, Brambilla M, Occhipinti M, Mazzeo L, Beninato T, Leporati R, Giani C, Cavalli C, Serino R, Prina MM, Bassetti A, Nasca V, di Mauro RM, Abate A, Manglaviti S, Dumitrascu AD, Liberti GD, Cassano TS, Ganzinelli M, Wu S, Garassino MC, de Braud FGM, Russo GL, Prelaj A. Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review. *Lung Cancer*. 2025 Jan;199:108051. doi: 10.1016/j.lungcan.2024.108051. Epub 2024 Dec 9.
- Catania C, **Proto C**, Bennati C, Grisanti S, Colantonio I, Petrella F, Filippi AR, Genova C, Piperno G, Teodorani N, Greco C, Sangalli C, Scotti V, Agustoni F, Olmetto E, Russano M, Agbaje V, Platania A, Di Pietro Paolo M, Borghetti P, Saddi J, Marcenaro M, Martini S, Russo A. Navigating chemotherapy and immunotherapy in early-stage lung cancer. A critical review and statements from INTERACTION group. *Crit Rev Oncol Hematol*. 2025 Feb 1;208:104633. doi: 10.1016/j.critrevonc.2025.104633. Online ahead of print.
- Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, Vicente Baz D, Sugawara S, Cobo M, Pérol M, Mascaux C, Poddubskaya E, Kitazono S, Hayashi H, Hong MH, Felip E, Hall R, Juan-Vidal O, Brungs D, Lu S, Garassino M, Chargualaf M, Zhang Y, Howarth P, Uema D, Lisberg A, Sands J; TROPION-Lung01 Trial Investigators (... **Proto C**...). Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. *J Clin Oncol*. 2025 Jan 20;43(3):260-272. doi: 10.1200/JCO-24-01544. Epub 2024 Sep 9.
- Ambrosini P, Miliziano D, Liberti GD, Lorenzini D, Marchesi S, Bassetti A, Tamborini E, Leporati R, Beninato T, Mazzeo L, Brambilla M, Ganzinelli M, Prelaj A, **Proto C**, Braud FG, Russo GL, Occhipinti M. Histologic Transformation of ALK-Rearranged Lung Adenocarcinomas to High-Grade LCNEC: Clinical and Molecular Description of Three Cases. *Clin Lung Cancer*. 2025 Jan;26(1):e11-e17. doi: 10.1016/j.clc.2024.11.012. Epub 2024 Nov 25.
- Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, Vicente Baz D, Sugawara S, Cobo M, Pérol M, Mascaux C, Poddubskaya E, Kitazono S, Hayashi H, Hong MH, Felip E, Hall R, Juan-Vidal O, Brungs D, Lu S, Garassino M, Chargualaf M, Zhang Y, Howarth P, Uema D, Lisberg A, Sands J; TROPION-Lung01 Trial Investigators (... **Proto C**...). Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. *J Clin Oncol*. 2025 Jan 20;43(3):260-272. doi: 10.1200/JCO-24-01544. Epub 2024 Sep 9.
- Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, Lee SH, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourão Dias J, Besse B, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yoshioka H, Yang JC, Thomas M, Nguyen D, Ou SI, Mukhedkar S, Prabhash K, D'Arcangelo M, Alatorre-Alexander J, Vázquez Limón JC, Alves S, Stroyakovskiy D, Peregudova M, Şendur MAN, Yazici O, Califano R, Gutiérrez Calderón V, de Marinis F, Passaro A, Kim SW, Gadgeel SM, Xie J, Sun T, Martinez M, Ennis M, Fennema E, Daksh M, Millington D, Leconte I, Iwasawa R, Lorenzini P, Baig M, Shah S, Bauml JM, Shreeve SM, Sethi S, Knoblauch RE, Hayashi H; MARIPOSA Investigators (...**Proto C**...). Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. *N Engl J Med*. 2024 Oct 24;391(16):1486-1498. doi: 0.1056/NEJMoa2403614. Epub 2024 Jun 26.
- Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, Zenke Y, Lee KH, Wang Q, Navarro A, Bernabe R, Buchmeier EL, Chang JW, Shiraishi Y, Goksu SS, Badzio A, Shi A, Daniel DB, Hoa NTT, Zemanova M, Mann H, Gowda H, Jiang H, Senan S; ADRIATIC Investigators (...**Proto C**...). Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. *N Engl J Med*. 2024 Oct 10;391(14):1313-1327. doi: 10.1056/NEJMoa2404873. Epub 2024 Sep 13.

8. Prelaj A, Miskovic V, Zanitti M, Trovo F, Genova C, Viscardi G, Rebuzzi SE, Mazzeo L, Provenzano L, Kosta S, Favali M, Spagnoletti A, Castelo-Branco L, Dolezal J, Pearson AT, Lo Russo G, **Proto C**, Ganzinelli M, Giani C, Ambrosini E, Turajlic S, Au L, Koopman M, Delaloge S, Kather JN, de Braud F, Garassino MC, Pentheroudakis G, Spencer C, Pedrocchi ALG. Ann Oncol. 2024 Jan;35(1):29-65. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review. doi: 10.1016/j.annonc.2023.10.125. Epub 2023 Oct 23.
9. Occhipinti M, Brambilla M, Di Liello R, Ambrosini P, Lobianco L, Leporati R, Salvatorezza M, Vitiello F, Marchesi S, Manglaviti S, Beninato T, Mazzeo L, **Proto C**, Prelaj A, Ferrara R, Della Corte CM, Lo Russo G, de Braud F, Ganzinelli M, Viscardi G. Crit Rev Oncol Hematol. 2024 Nov;203:104481. Unleashing precision: A review of targeted approaches in pleural mesothelioma. doi: 10.1016/j.critrevonc.2024.104481. Epub 2024 Aug 17.
10. Pizzutilo EG, Agostara AG, Oresti S, Signorelli D, Stabile S, Lauricella C, Motta V, Amatu A, Ruggieri L, Brambilla M, Occhipinti M, **Proto C**, Giusti R, Filetti M, Genova C, Barletta G, Gelsomino F, Bennati C, Siringo M, Di Fazio GR, Russano M, Montrone M, Gariazzo E, Roca E, Bordi P, Delmonte A, Scimone A, Belluomini L, Mazzoni F, Carta A, Pelizzari G, Viscardi G, Morgillo F, Gelibter A, Gori S, Berardi R, Cortinovis D, Ardizzoni A, Veronese SM, Sartore-Bianchi A, Giannetta LG, Cerea G, Siena S. Activity of osimertinib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO). ESMO Open. 2024 Jun;9(6):103592. doi: 10.1016/j.esmoop.2024.103592. Epub 2024 Jun 14.
11. **C. Proto**, M. Ganzinelli, S. Manglaviti, M. Imbimbo, G. Galli, M. Marabese, F. Zollo, M.F. Alvisi, M. Perrino, N. Cordua, F. Borea, F. de Vincenzo, A. Chella, S. Cappelli, E. Pardini, Z. Ballatore, A. Lucarelli, E. Ambrosini, M. Giuliano, E. Pietrolungo, C. Mulargiu, A. Fabbri, A. Prelaj, M. Occhipinti, M. Brambilla, L. Mazzeo, T. Beninato, R. Vigorito, M. Ruggirello, F.G. Greco, G. Calareso, D. Miliziano, E. Rulli, I. De Simone, V. Torri, F.G.M. de Braud, G. Pasello, P. De Placido, R. Berardi, I. Petrini, P. Zucali, M.C. Garassino, G. Lo Russo Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVANT phase II trial (NCT03921671) Annals of Oncology (2024), doi: <https://doi.org/10.1016/j.annonc.2024.06.002>.
12. Miceli R, Eriksson H, Lo Russo G, Alfieri S, Moksnes Bjaanæs M, Pietrantonio F, De Cecco L, Prelaj A, **Proto C**, Franzén J, McDonnell D, Berenguer Pina JJ, Beninato T, Mazzeo L, Giannatempo P, Verzoni E, Crown J, Helland Å, Eustace A. Gender Difference in side Effects of Immunotherapy: a possible clue to optimize cancer treatment (G-DEFINER): study protocol of an observational prospective multicenter study. Acta Oncol. 2024 Apr 21;63:213-219. doi: 10.2340/1651-226X.2024.24179.
13. Leporati R, Miliziano D, Beninato T, Mazzeo L, Manglaviti S, Brambilla M, Occhipinti M, Prelaj A, **Proto C**, Lo Russo G. Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs. Tumori. 2024 Apr 16;3008916241246659. doi: 10.1177/03008916241246659. Online ahead of print.
14. Cerbone L, Delfanti S, Crivellari S, De Angelis AM, Mazzeo L, **Proto C**, Occhipinti M, Lo Russo G, Dellepiane C, Biello F, Alabiso I, Verderame F, Gauna R, De Simone I, Cuppone F, Petraglia S, Pasello G, Ceresoli GL, Garassino MC, Torri V, Grosso F. Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund. Tumori. 2024 Feb 19;3008916241229287. doi: 10.1177/03008916241229287. Online ahead of print.
15. Prelaj A, Ganzinelli M, Provenzano L, Mazzeo L, Viscardi G, Metro G, Galli G, Agustoni F, Corte CMD, Spagnoletti A, Giani C, Ferrara R, **Proto C**, Brambilla M, Dumitrascu AD, Inno A, Signorelli D, Pizzutilo EG, Brighenti M, Biello F, Bennati C, Toschi L, Russano M, Cortellini A, Catania C, Bertolini F, Berardi R, Cantini L, Pecci F, Macerelli M, Emili R, Bareggi C, Verderame F, Lugini A, Pisconti S, Buzzacchino F, Aieta M, Tartarone A, Spinelli G, Vita E, Grisanti S, Trovò F, Auletta P, Lorenzini D, Agnelli L, Sangaletti S, Mazzoni F, Calareso G, Ruggirello M, Greco GF, Vigorito R, Occhipinti M, Manglaviti S, Beninato T, Leporati R, Ambrosini P, Serino R, Silvestri C, Zito E, Pedrocchi ACL, Miskovic V, de Braud F, Pruneri G, Lo Russo G, Genova C, Vingiani A. APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research. Clin Lung Cancer. 2024 Mar;25(2):190-195. doi: 10.1016/j.clcc.2023.12.012. Epub 2023 Dec 22.
16. Ceresoli GL, Rossi G, Agustoni F, Bonomi L, Borghetti P, Bulotta A, Casartelli C, Cerea

- G, Colonese F, Del Signore E, Finocchiaro G, Gianoncelli L, Grisanti S, Maiolani M, Pagni F, **Proto C**, Rijavec E, Vittimberga I, Arcangeli S, Filippi AR. Management of patients with extensive small-cell lung cancer in the immunotherapy era: an Italian consensus through a Delphi approach. *Crit Rev Oncol Hematol*. 2024 Jan 31:104247. doi: 10.1016/j.critrevonc.2023.104247. Online ahead of print.
17. Christopoulos P, Girard N, **Proto C**, Soares M, Lopez PG, van der Wekken AJ, Popat S, Diels J, Schioppa CA, Sermon J, Rahhali N, Pick-Lauer C, Adamczyk A, Penton J, Wislez M. Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations. *Cancers (Basel)*. 2023 Nov 8;15(22):5326. doi: 10.3390/cancers15225326.
  18. Manglaviti S, Bini M, Apollonio G, Zecca E, Galli G, Sangaletti S, Labianca A, Sottotetti E, Brambilla M, Occhipinti M, **Proto C**, Prelaj A, Signorelli D, De Toma A, Viscardi G, Beninato T, Mazzeo L, Bottiglieri A, Leporati R, Fotia G, Ganzinelli M, Portararo P, Garassino MC, de Braud FGM, Lo Russo G, Torri V, Ferrara R. High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors. *Lung Cancer*. 2023 Dec;186:107417. doi: 10.1016/j.lungcan.2023.107417. Epub 2023 Oct 29.
  19. Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourão Dias J, Filip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N; PAPILLON Investigators (... **Proto C**...). Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. *N Engl J Med*. 2023 Nov 30;389(22):2039-2051. doi: 10.1056/NEJMoa2306441. Epub 2023 Oct 21.
  20. Brambilla M, Beninato T, Piemontese A, Mazzeo L, Pircher CC, Manglaviti S, Ambrosini P, Signorelli D, Lorenzini D, Prelaj A, Ferrara R, **Proto C**, Lo Russo G, Pizzutilo EG, Ganzinelli M, Grande I, Capone I, Di Mauro RM, Conca E, Dumitrescu AD, Zanella C, Leporati R, Rota S, Garassino MC, Marchetti P, de Braud FM, Occhipinti M. Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations. *Clin Lung Cancer*. 2023 Nov;24(7):631-640.e2. doi: 10.1016/j.clc.2023.08.004. Epub 2023 Aug 23.
  21. Pecci F, Cantini L, Cognigni V, Perrone F, Mazzaschi G, Agostinelli V, Mentrasti G, Favari E, Maffezzoli M, Cortellini A, Rossi F, Chiariotti R, Venanzi FM, Lo Russo G, Galli G, **Proto C**, Ganzinelli M, Tronconi F, Morgese F, Campolucci C, Moretti M, Vignini A, Tiseo M, Minari R, Rocchi MLB, Buti S, Berardi R. Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study. *Oncologist*. 2023 Oct 5:oyad273. doi: 10.1093/oncolo/oyad273. Online ahead of print.
  22. Prelaj A, Miskovic V, Zanitti M, Trovo F, Genova C, Viscardi G, Rebuzzi SE, Mazzeo L, Provenzano L, Kosta S, Favali M, Spagnoletti A, Castelo-Branco L, Dolezal J, Pearson AT, Lo Russo G, **Proto C**, Ganzinelli M, Giani C, Ambrosini E, Turajlic S, Au L, Koopman M, Delaloge S, Kather JN, de Braud F, Garassino MC, Pentheroudakis G, Spencer C, Pedrocchi ALG. Artificial Intelligence for predictive biomarker discovery in immuno-oncology: a systematic review. *Ann Oncol*. 2023 Oct 23:S0923-7534(23)04331-4. doi: 10.1016/j.annonc.2023.10.125. Online ahead of print.
  23. Catania C, Filippi AR, Sangalli C, Piperno G, Russano M, Greco C, Scotti V, **Proto C**, Bennati C, Di Pietro Paolo M, Platania A, Olmetto E, Agustoni F, Teodorani N, Agbaje V, Russo A. New options and open issues in the management of unresectable stage III and in early-stage NSCLC: a report from an expert panel of Italian medical and radiation oncologists - INTERACTION GROUP. *Crit Rev Oncol Hematol*. 2023 Aug 24:104108. doi: 10.1016/j.critrevonc.2023.104108. Online ahead of print.
  24. Vingiani A, Agnelli L, Duca M, Lorenzini D, Damian S, **Proto C**, Niger M, Nichetti F, Tamborini E, Perrone F, Piccolo A, Manoukian S, Azzollini J, Brambilla M, Colombo E, Lopez S, Vernieri C, Marra F, Conca E, Busico A, Capone I, Bozzi F, Angelini M, Devecchi A, Salvatori R, De Micheli V, Baggi A, Pasini S, Jommi C, Ladisa V, Apolone G, De Braud F, Pruneri G. Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care. *JCO Precis Oncol*. 2023 Jul;7:e2300067. doi: 10.1200/PO.23.00067.
  25. Lo Russo G, Prelaj A, Dolezal J, Beninato T, Agnelli L, Triulzi T, Fabbri A, Lorenzini D, Ferrara R, Brambilla M, Occhipinti M, Mazzeo L, Provenzano L, Spagnoletti A, Viscardi G, Sgambelluri F, Brich S, Miskovic V, Pedrocchi ALG, Trovo F, Manglaviti S, Giani C, Ambrosini P, Leporati R, Franza A, McCulloch J, Torelli T, Anichini A, Mortarini R, Trinchieri G, Pruneri G, Torri V, De Braud F, **Proto C\***, Ganzinelli M,

- Garassino MC. J PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis. *Immunother Cancer*. 2023 Jun;11(6):e006833. doi: 10.1136/jitc-2023-006833. (\* Last name, equal contribute to the last author)
26. **Proto C**, Manglaviti S, Lo Russo G, Musca M, Galli G, Imbimbo M, Perrino M, Cordua N, Rulli E, Ballatore Z, Maso AD, Chella A, Sbrana A, Prelaj A, Ferrara R, Occhipinti M, Brambilla M, De Toma A, Mazzeo L, Beninato T, Signorelli D, Massa G, Greco FG, Calareso G, Miliziano D, Di Mauro RM, Mella G, Lucarelli A, Paggio A, Galli F, Torri V, de Braud FGM, Pasello G, Petrini I, Berardi R, Ganzinelli M, Garassino MC, Zucali PA. STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines. *J Thorac Oncol*. 2023 Apr 23:S1556-0864(23)00513-0. doi: 10.1016/j.jtho.2023.04.009. Online ahead of print.
  27. Lococo F, Cancellieri A, Chiappetta M, Leonetti A, Cardillo G, Zanelli F, Mangiameli G, Toschi L, Guggino G, Romano FJ, Leuzzi G, **Proto C**, Spaggiari L, De Marinis F, Vita E, Ampollini L, Margaritora S, Tiseo M, Bria E. Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results. *Clin Lung Cancer*. 2023 Mar 20:S1525-7304(23)00044-X. doi: 10.1016/j.clc.2023.03.008. Online ahead of print.
  28. Prelaj A, Galli EG, Miskovic V, Pesenti M, Viscardi G, Pedica B, Mazzeo L, Bottiglieri A, Provenzano L, Spagnoletti A, Marinacci R, De Toma A, **Proto C**, Ferrara R, Brambilla M, Occhipinti M, Manglaviti S, Galli G, Signorelli D, Giani C, Beninato T, Pircher CC, Rametta A, Kosta S, Zanitti M, Di Mauro MR, Rinaldi A, Di Gregorio S, Antonia M, Garassino MC, de Braud FGM, Restelli M, Lo Russo G, Ganzinelli M, Trovò F, Pedrocchi ALG. Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients. *Front Oncol*. 2023 Jan 23;12:1078822. doi: 10.3389/fonc.2022.1078822. eCollection 2022.
  29. Catania C, **Piperino** G, Russo A, Greco C, Agustoni F, Scotti V, **Proto C**, Sangalli C, Patani F, Santacaterina A, Di Pietro Paolo M, Agresti B, Filippi AR, Ramella S. Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era. *Crit Rev Oncol Hematol*. 2022 Jun;174:103684. doi: 10.1016/j.critrevonc.2022.103684. Epub 2022 Apr 21. PMID: 35462031 Review.
  30. G Lo **Russo**, F Sgambelluri, A Prelaj, F Galli, S Manglaviti, A Bottiglieri, RM Di Mauro, R Ferrara, G Galli, D Signorelli, A De Toma, M Occhipinti, M Brambilla, E Rulli, T Triulzi, T Torelli, L Agnelli, S Brich, A Martinetti, AD Dumitrascu, V Torri, G Pruneri, A Fabbri, F de Braud, A Anichini, **C Proto**, M Ganzinelli, R Mortarini, MC Garassino. PEOPLE (NTC03447678) a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers. *ESMO Open* 2022;7(6):100645.
  31. Viscardi G, Tralongo AC, Massari F, Lambertini M, Mollica V, Rizzo A, Comito F, Di Liello R, Alfieri S, Imbimbo M, Della Corte CM, Morgillo F, Simeon V, Lo Russo G, **Proto C**, Prelaj A, De Toma A, Galli G, Signorelli D, Ciardiello F, Remon J, Chaput N, Besse B, de Braud F, Garassino MC, Torri V, Cini M, Ferrara R. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. *Eur J Cancer*. 2022 Dec;177:175-185. doi: 10.1016/j.ejca.2022.09.031. Epub 2022 Oct 5. PMID: 36368251 Review.
  32. Signorelli D, Ghidotti P, **Proto C**, Brambilla M, De Toma A, Ferrara R, Galli G, Ganzinelli M, Lorusso G, Prelaj A, Occhipinti M, Viscardi G, Capizzuto V, Pontis F, Petraroia I, Ferretti AM, Colombo MP, Torri V, Sozzi G, Garassino MC, Jachetti E, Fortunato O. Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC. *Front Immunol*. 2022 Sep 20;13:987639. doi: 10.3389/fimmu.2022.987639.
  33. Galli G, Corsetto PA, **Proto C**, Lo Russo G, Ganzinelli M, Rulli E, Legramandi L, Morelli D, Ferrara R, Prelaj A, Signorelli D, De Toma A, Brambilla M, Occhipinti M, Manglaviti S, Boeri M, Martinetti A, Vingiani A, Colombo MP, Rizzo AM, Torri V, de Braud F, Sangaletti S, Sica A, Garassino MC. Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer. *Clin Lung Cancer*. 2022 Nov;23(7):e489-e499. doi: 10.1016/j.clc.2022.07.010. Epub 2022 Jul 21.
  34. Prelaj A, Bottiglieri A, Bhat G, Washington R, Calareso G, Greco GF, Ferrara R, Brambilla M, De Toma A, Occhipinti M, Manglaviti S, Soro A, Ganzinelli M, Lo Russo G, **Proto C**. Case Report: Exceptional Response to Pozotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation. *Front Oncol*. 2022 Jun 8;12:902967.

35. Zattarin E, Manglaviti S, Apollonio G, Beninato T, Mazzeo L, Massa G, Bottiglieri A, Galli E, De Toma A, Occhipinti M, Brambilla M, Ferrara R, Ganzinelli M, **Proto C**, Garassino MC, de Braud F, Lo Russo G, Prelaj A. Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. *Future Oncol* 2022; 18(23):2593-2604.
36. Piccirillo MC, Bonanno L, Garassino MC, Esposito G, Dazzi C, Cavanna L, Burgio MA, Rosetti F, Rizzato S, Morgillo F, Cinieri S, Vecchia A, Papi M, Tonini G, Gebbia V, Ricciardi S, Pozzessere D, Ferro A, **Proto C**, Costanzo R, D'Arcangelo M, Proietto M, Gargiulo P, Di Liello R, Arenare L, De Marinis F, Crinò L, Ciardiello F, Normanno N, Gallo C, Perrone F, Gridelli C, Morabito A. Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous non-small cell lung cancer. The BEVERLY multicenter randomized phase III trial. *J Thorac Oncol*. 2022 Jun 1:S1556-0864(22)00268-4. doi: 10.1016/j.jtho.2022.05.008. Online ahead of print.
37. Manglaviti S, Brambilla M, Signorelli D, Ferrara R, Lo Russo G, **Proto C**, Galli G, De Toma A, Occhipinti M, Viscardi G, Beninato T, Zattarin E, Bini M, Lobefaro R, Massa G, Bottiglieri A, Apollonio G, Sottotetti E, Di Mauro RM, Trevisan B, Ganzinelli M, Fabbri A, de Braud FGM, Garassino MC, Prelaj A. Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology. *Clin Lung Cancer*. 2022 Jan;23(1):e17-e28. doi: 10.1016/j.clcc.2021.06.013. Epub 2021 Jul 5. PMID: 34334296
38. Azzollini J, Vingiani A, Agnelli L, Tamborini E, Perrone F, Conca E, Capone I, Busico A, Peissel B, Rosina E, Ducceschi M, Mantiero M, Lopez S, Raspagliesi F, Nigam M, Duca M, Damian S, **Proto C**, de Braud F, Pruneri G, Manoukian S. Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model. *Front Oncol*. 2022 Apr 8;12:857515. doi: 10.3389/fonc.2022.857515. eCollection 2022
39. Prelaj A, Boeri M, Robuschi A, Ferrara R, **Proto C**, Lo Russo G, Galli G, De Toma A, Brambilla M, Occhipinti M, Manglaviti S, Beninato T, Bottiglieri A, Massa G, Zattarin E, Gallucci R, Galli EG, Ganzinelli M, Sozzi G, de Braud FGM, Garassino MC, Restelli M, Pedrocchi ALG, Trovo' F. Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy. *Cancers (Basel)*. 2022 Jan 16;14(2):435. doi: 10.3390/cancers14020435.
40. Prinzi N, Rossi RE, **Proto C**, Leuzzi G, Raimondi A, Torchio M, Milione M, Corti F, Colombo E, Prisciandaro M, Cascella T, Spreafico C, Beninato T, Coppa J, Lo Russo G, Di Bartolomeo M, de Braud F, Pusceddu S. Recent Advances in the Management of Typical and Atypical Lung Carcinoids. *Clin Lung Cancer*. 2021 May;22(3):161-169.
41. Ferrara R, Signorelli D, **Proto C**, Prelaj A, Garassino MC, Lo Russo G. Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. *Transl Lung Cancer Res*. 2021 Jun;10(6):2955-2969.
42. Petrelli F, Ferrara R, Signorelli D, Ghidini A, **Proto C**, Roudi R, Sabet MN, Facelli S, Garassino MC, Luciani A, Roviello G. Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis. *Immunotherapy*. 2021 May;13(7):621-631. doi: 10.2217/imt-2020-0224. Epub 2021 Mar 29. PMID: 33775103
43. Prelaj A, Bottiglieri A, **Proto C**, Lo Russo G, Signorelli D, Ferrara R, Galli G, De Toma A, Viscardi G, Brambilla M, Lobefaro R, Nichetti F, Manglaviti S, Occhipinti M, Labianca A, Ganzinelli M, Gallucci R, Zilembo N, Greco GF, Torri V, de Braud F, Garassino MC. Pozotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. *Eur J Cancer*. 2021 2:S0959-8049(21)00146-5.
44. Occhipinti M, Brambilla M, Galli G, Manglaviti S, Giammaruco M, Prelaj A, Ferrara R, De Toma A, **Proto C**, Beninato T, Zattarin E, Lo Russo G, Gelibter AJ, Simmaco M, Preissner R, Garassino MC, De Braud F, Marchetti P. Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. *J. Pers. Med*. 2021, 11(5), 424
45. De Toma A, Lo Russo G, Signorelli D, Pagani F, Randon G, Galli G, Prelaj A, Ferrara R, **Proto C**, Ganzinelli M, Zilembo N, de Braud F, Garassino MC. Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. *Crit Rev Oncol Hematol*. 2021 Mar 16;160:103299.
46. Prelaj A, Pircher CC, Massa G, Martelli V, Corrao G, Lo Russo G, **Proto C**, Ferrara R, Galli G, De Toma A, Genova C, Jerezek-Fossa BA, de Braud F, Garassino MC and Rebutti SE. Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. *Cancers* 2021, 13, 1300.

47. Lobefaro R, Viscardi G, Di Liello R, Massa G, Iacovino ML, Sparano F, Della Corte CM, Ferrara R, Signorelli D, **Proto C**, Prelaj A, Galli G, De Toma A, Brambilla M, Ganzinelli M, Trevisan B, Ciardiello F, de Braud F, Morgillo F, Garassino M, Lo Russo G. Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: the role of clinical-pathological variables and inflammatory biomarkers, Lung Cancer (2021),
48. Ferrara R, Signorelli D, **Proto C**, Prelaj A, Garassino MC, Giuseppe Lo Russo G. Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. Transl Lung Cancer Res 2020
49. Bersanelli M, Buti S, Giannarelli D, Leonetti A, Cortellini A, Russo GL, Signorelli D, Toschi L, Milella M, Pilotto S, Bria E, **Proto C**, Marinello A, Randon G, Rossi S, Vita E, Sartori G, D'Argento E, Qako E, Giaiacopi E, Ghilardi L, Bettini AC, Rapacchi E, Mazzoni F, Lavacchi D, Scotti V, Ciccone LP, De Tursi M, Di Marino P, Santini D, Russano M, Bordi P, Di Maio M, Audisio M, Filetti M, Giusti R, Berardi R, Fiordoliva I, Cerea G, Pizzutilo EG, Bearz A, De Carlo E, Cecere F, Renna D, Camisa R, Caruso G, Ficorella C, Banna GL, Cortinovis D, Brighenti M, Garassino MC, Tiseo M. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. Lung Cancer. 2020 Dec;150:123-131.
50. De Toma A, Lo Russo G, Signorelli D, Ferrara R, Prelaj A, Galli G, Viscardi G, Trevian B, Ganzinelli M, Zilembo N, de Braud F, Garassino MC and **Proto C**. Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy. European Oncology & Haematology. 2020;16(1):39–43
51. Trama A\*, **Proto C\***, Whisenant JG, Torri V, Cortellini A, Michielin O, Barlesi F, Dingemans AC, Van Meerbeeck J, Pancaldi V, Mazieres J, Soo RA, Leighl NB, Peters S, Wakelee H, Horn L, Hellmann M, Wong SK, Garassino MC, Baena J. Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERA-VOLT Experience. Cancer Cell. 2020 Nov 9;38(5):602-604. (*\*First name, equal contribute to the first author*)
52. Mountzios G, de Toma A, Economopoulou P, Friedlaender A, Banini M, Lo Russo G, Baxevas P, Roila F, Banna GL, Christopoulou A, Jimenez B, Collazo-Lorduy A, Linardou H, Calles A, Galetta D, Addeo A, Camerini A, Pizzutilo P, Kosmidis P, Garassino MC, **Proto C**, Signorelli D, Metro G. Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. Clin Lung Cancer. 2020 Oct 14:S1525-7304(20)30297-7
53. Signorelli D\*, **Proto C\***, Botta L, Trama A, Tiseo M, Pasello G, Lo Russo G, Fabbri A, Imbimbo M, Busico A, Prelaj A, Ferrara R, Galli G, De Toma A, Tamborini E, Pastorino U, de Braud F, Gatta G, Garassino MC, Ganzinelli M. SMO mutations confer poor prognosis in malignant pleural mesothelioma. Transl Lung Cancer Res. 2020 Oct;9(5):1940-1951. (*\*First name, equal contribute to the first author*)
54. Ferrara R, Naigeon M, Auclin E, Duchemann B, Cassard L, Jouniaux JM, Boselli L, Grivel J, Desnoyer A, Mezquita L, Texier M, Caramella C, Hendriks L, Planchard D, Remon J, Sangaletti S, **Proto C**, Garassino MC, Soria JC, Marabelle A, Voisin AL, Farhane S, Besse B, Chaput N. Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. Clin Cancer Res. 2020 Sep 4.
55. Cortellini A, Friedlaender A, Banna GL, Porzio G, Bersanelli M, Cappuzzo F, Aerts JGJV, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Berardi R, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Inno A, Di Marino P, Mansueto G, Zoratto F, Santoni M, Tudini M, Ghidini M, Filetti M, Catino A, Pizzutilo P, Sala L, Occhipinti MA, Citarella F, Marco R, Torniai M, Cantini L, Follador A, Sforza V, Nigro O, Ferrara MG, D'Argento E, Leonetti A, Pettruti L, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Bertolini F, Della Gravara L, Dal Bello MG, Belderbos RA, De Filippis M, Cecchi C, Ricciardi S, Dionisi C, De Toma A, **Proto C**, Addeo A, Cantale O, Ricciuti B, Genova C, Morabito A, Santini D, Ficorella C, Cannita K. Immune-related adverse events of pembrolizumab in a large real-world cohort of NSCLC patients with a PD-L1 expression  $\geq 50\%$  and their relationship with clinical outcomes. Clinical Lung Cancer, Vol. 21, No. 6, 498-508
56. Prelaj A\*, **Proto C\***, Lo Russo G, Signorelli D, Ferrara R, Mensah M, Galli G, De Toma A, Viscardi G, Brambilla M, Lobefaro R, Trevisan B, Trovò F, Torri V, Sozzi G, Garassino MC, Boeri M. Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. Transl Lung Cancer Res 2020;9(3):617-628. (*First name, equal contribute to the first author*).

57. Cortellini A, Tiseo M, Banna GL, Cappuzzo F, Aerts JGJV, Barbieri F, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Santini D, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Santoni M, Tudini M, Rijavec E, Filetti M, Catino A, Pizzutilo P, Sala L, Citarella F, Marco R, Torniai M, Cantini L, Targato G, Sforza V, Nigro O, Ferrara MG, D'Argento E, Buti S, Bordi P, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Della Grava L, Dal Bello MG, Belderbos RA, Bironzo P, Carnio S, Ricciardi S, Grieco A, De Toma A, **Proto C**, Friedlaender A, Cantale O, Ricciuti B, Addeo A, Metro G, Ficorella C, Porzio G. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of  $\geq 50$ . *Cancer Immunol Immunother*. 2020 Nov;69(11):2209-2221.
58. Vernieri C, Ganzinelli M, Rulli E, Farina G, Bettini AC, Bareggi C, Rosso L, Signorelli D, Galli G, Lo Russo G, **Proto C**, Moro M, Indraccolo S, Busico A, Sozzi G, Torri V, Marabese M, Massimo B, Garassino MC; TAILOR trialists. LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. *ESMO Open*. 2020 May;5(3):e000748.
59. Trama A, **Proto C**, Signorelli D, Garassino MC, Lo Russo G, Ganzinelli M, Prelaj A, Mensi C, Gangemi M, Gennaro V, Chellini E, Caldarella A, Angelillo IF, Ascoli V, Pascucci C, Tagliabue G, Cusimano R, Bella F, Falcini F, Merler E, Masanotti G, Ziino A, Michiara M, Gola G, Storch C, Mangone L, Vitale MF, Cirilli C, Tumino R, Scuderi T, Fanetti AC, Piffer S, Tiseo M, Gatta G, Botta L; LUME study WG. Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study. *Thorac Cancer*. 2020 Jun;11(6):1661-1669.
60. Prelaj A, Lo Russo G, **Proto C**, Signorelli D, Ferrara R, Galli G, De Toma A, Randon G, Pagani F, Trevisan B, Ganzinelli M, Zilembo N, Montrone M, Longo V, Pesola F, Pizzutilo P, Del Bene G, Varesano N, Galetta D, Torri V, Garassino MC, Di Maio M, Catino A. DiM: prognostic score for second or further-line immunotherapy in advanced non-small-cell lung cancer: an external validation. *Clinical Lung Cancer*, Vol. 21, No. 5, e337-48
61. Facchinetti F, Mazzaschi G, Barbieri F, Passiglia F, Mazzoni F, Berardi R, **Proto C**, Cecere FL, Pilotto S, Scotti V, Rossi S, Del Conte A, Vita E, Bennati C, Ardizzoni A, Cerea G, Migliorino MR, Sala E, Camerini A, Bearz A, De Carlo E, Zanelli F, Guaitoli G, Garassino MC, Ciccone LP, Sartori G, Toschi L, Dall'Olio FG, Landi L, Pizzutilo EG, Bartoli G, Baldessari C, Novello S, Bria E, Cortinovis DL, Rossi G, Rossi A, Banna GL, Camisa R, Di Maio M, Tiseo M. First-line pembrolizumab in advanced non-small cell lung cancer patients with poor Performance status. *European Journal of Cancer* 130 (2020) 155-167
62. Nichetti F, Ligorio F, Zattarin E, Signorelli D, Prelaj A, **Proto C**, Galli G, Marra A, Apollonio G, Porcu L, de Braud F, Lo Russo G, Ferrara R, Garassino MC. Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients. *Cancers* 2020, 12, 67.
63. Prelaj A, Ferrara R, Rebuzzi SE, **Proto C**, Signorelli D, Galli G, De Toma A, Randon G, Pagani F, Viscardi G, Brambilla M, Trevisan B, Ganzinelli M, Martinetti A, Gallucci R, Di Mauro RM, Molino G, Zilembo N, Torri V, de Braud FM, Garassino MC, Lo Russo G. EPSiLoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. *Cancers* 2019, 11, 1954..
64. Galli G, De Toma A, Pagani F, Randon G, Trevisan B, Prelaj A, Ferrara R, **Proto C**, Signorelli D, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G. Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. *Lung Cancer*. 2019 Nov;137:38-42.
65. Galli G, **Proto C**, Cossa M, Valeri B, Sdao S, Signorelli D, Imbimbo M, de Braud F, Garassino MC, Lo Russo G. Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer. *Tumori*. 2019 Dec;105(6)
66. **Proto C**, Signorelli D, Mallone S, Prelaj A, Lo Russo G, Imbimbo M, Galli G, Ferrara R, Ganzinelli M, Leuzzi G, Greco FG, Calareso G, Botta L, Gatta G, Garassino M, Trama A. The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma. *Clin Lung Cancer*. 2019 Nov;20(6):e652-e660.
67. Galli G\*, **Proto C\***, Signorelli D, Imbimbo M, Ferrara R, Prelaj A, De Toma A, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G. Characterization of patients

- with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. *Future Oncol.* 2019 Aug;15(23):2743-2757. *(First name, equal contribute to the first author).*
68. Galli G, Triulzi T, **Proto C**, Signorelli D, Imbimbo M, Poggi M, Fucà G, Ganzinelli M, Vitali M, Palmieri D, Tessari A, de Braud F, Garassino MC, Colombo MP, Lo Russo G. Association between Antibiotic-Immunotherapy Exposure Ratio and outcome in metastatic Non Small Cell Lung Cancer. *Lung Cancer* 132 (2019) 72–78
  69. Platania M, Pasin F, Porcu L, Boeri M, Verderame F, Modena Y, Del Conte A, Nichetti F, Garassino MC, Martinetti A, Sottotetti E, Cavanna L, Vattei E, Pozzessere D, Bertolini A, Irtelli L, Verri C, Sozzi G, **Proto C**, Pastorino U, Torri V, Fraccon AP, Spinnato F, Signorelli D, Lorusso G, Tuzi A, Gallucci R, cinieri S, Mencoboni M, Antonelli P, Giacomelli L, de Braud F. Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: the MA.NI.LA. multicenter, randomized, controlled, phase II trial. *Lung Cancer* 132 (2019) 17-23
  70. Fucà G, Galli G, Poggi M, Lo Russo G, **Proto C**, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Sica A, Torri V, Colombo MP, Vernieri C, Balsari A, de Braud F, Garassino MC, Signorelli D. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. *ESMO Open*. 2019 Feb 27;4(1):e000457.
  71. **Proto C**, Ferrara R, Signorelli D, Lo Russo G, Galli G, Imbimbo M, Prelaj A, Zilembo N, Ganzinelli M, Pallavicini LM, De Simone I, Colombo MP, Sica A, Torri V, Garassino MC. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. *Cancer Treat Rev.* 2019 Mar 28;75:39-51.
  72. Crinò L, Bronte G, Bidoli P, Cravero P, Minenza E, Cortesi E, Garassino MC, **Proto C**, Cappuzzo F, Grossi F, Tonini G, Sarobba MG, Pinotti G, Numico G, Samaritani R, Ciuffreda L, Frassoldati A, Bregni M, Santo A, Piantadosi F, Illiano A, De Marinis F, Tamberi S, Giannarelli D, Delmonte A. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. *Lung Cancer.* 2019 Mar;129:35-40.
  73. Boeri M\*, Milione M\*, **Proto C\***, Signorelli D, Russo GL, Galeone C, Verri C, Mensah M, Centonze G, Martinetti A, Sottotetti E, Pastorino U, Garassino MC, Sozzi G. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. *Clin Cancer Res.* 2019 Jan 7, 2166-2173. *(First name, equal contribute to the first author).*
  74. Passaro A, Prelaj A, Bonanno L, Tiseo M, Tuzi A, **Proto C**, Chiari R, Rocco D, Genova C, Sini C, Cortinovis D, Pilotto S, Landi L, Bennati C, Camerini A, Toschi L, Putzu C, Cerea G, Spitaleri G, Cappuzzo F, de Marinis F. Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. *Clin Lung Cancer.* 2018 Nov 20.
  75. Imbimbo M, Ottaviano M, Vitali M, Fabbri A, Leuzzi G, Fiore M, Franceschini D, Pasello G, Perrino M, Schiavon M, Pruner G, Dei Tos AP, Sangalli C, Garassino MC, Berardi R, Alessi A, Calareso G, Petrini I, Scorsetti M, Scotti V, Rosso L, Rea F, Pastorino U, Casali PG, Ramella S, Ricardi U, Abate-Daga L, Torri V, Trama A, Palmieri G, Marino M, Zucali PA; TYME network collaborators: Alloisio M, Apolone G, Ardizzoni A, Benvenuti M, Berruti A, Breda C, Buzzoni C, Calabrese F, Caraceni A, Cardillo G, Casadio C, Cassi E, Caterino M, Cecere FL, Chiti A, Crippa A, Curcio C, De Braud F, De Pas T, Di Tommaso L, Evoli A, Facciolo F, Galli G, Lopez I, Lo Russo G, Luisella S, Luzzi L, Mantovani C, Marchianò A, Margaritora S, Monaco R, Morandi U, Novellino L, Piras MT, Porcu L, Priola A, **Proto C**, Battista Ratto G, Rena O, Rinaldi S, Roca E, Rocco G, Ruffini E, Signorelli D, Solli P, Spaggiari L, Stefani A, Veltri A, Vespro V, Zilembo N.vBest practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). *Cancer Treat Rev.* 2018 Dec;71:76-87.
  76. Fucà G, Galli G, Poggi M, Lo Russo G, **Proto C**, Imbimbo M, Vitali M, Ganzinelli M, Lanti C, Molino G, Stangoni F, Zilembo N, de Braud F, Garassino MC, Signorelli D. Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. *Target Oncol.* 2018 Dec;13(6):795-800.
  77. Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group: ... **Proto C**... First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. *N Engl J Med.* 2018 Dec 6;379(23):2220-2229.

78. Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, **Proto C**, Pruneri G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A, Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino MC. Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. *Clin Cancer Res*. 2019 Feb 1;25(3):989-999.
79. Grossi F, Crinò L, Logroscino A, Canova S, Delmonte A, Melotti B, **Proto C**, Gelibter A, Cappuzzo F, Turci D, Gamucci T, Antonelli P, Marchetti P, Santoro A, Giusti S, Di Costanzo F, Giustini L, Del Conte A, Livi L, Giannarelli D, de Marinis F. Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. *Eur J Cancer*. 2018 Sep;100:126-134.
80. Galli G, Corrao G, Imbimbo M, **Proto C**, Signorelli D, Ganzinelli M, Zilembo N, Vitali M, de Braud F, Garassino MC, Lo Russo G. Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review. *Lung Cancer*. 2018 Jan;115:135-142.
81. Vitali M, Ripamonti CI, Roila F, **Proto C**, Signorelli D, Imbimbo M, Corrao G, Brissa A, Rosaria G, de Braud F, Garassino MC, Lo Russo G. Cognitive impairment and chemotherapy: a brief overview. *Crit Rev Oncol Hematol*. 2017 Oct;118:7-14.
82. **Proto C**, Lo Russo G, Corrao G, Ganzinelli M, Facchinetti F, Minari R, Tiseo M, Garassino MC. Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms. *Tumori*. 2017 Jul 31;103(4):325-337.
83. Lo Russo G, Imbimbo M, Corrao G, **Proto C**, Signorelli D, Vitali M, Ganzinelli M, Botta L, Zilembo N, de Braud F, Garassino MC. Concomitant EML4-ALK rearrangement and EGFR mutation in non small cell lung cancer patients: A literature review of 100 cases. *Oncotarget*. 2017 Apr 26, 8, (NO 35), 59889-59900.
84. Facchinetti F, **Proto C**, Minari R, Garassino M, Tiseo M. Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer. *Handb Exp Pharmacol*. 2017 Mar 23.
85. **Proto C**, Imbimbo M, Gallucci R, Brissa A, Signorelli D, Vitali M, Macerelli M, Corrao G, Ganzinelli M, Greco FG, Garassino MC, Lo Russo G. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for the treatment of Central Nervous System metastases from Non Small Cell Lung Cancer. The present and the future. *Translational Lung Cancer Research* (review)
86. Lo Russo G, Pusceddu S, Prinzi N, Imbimbo M, **Proto C**, Signorelli D, Vitali M, Ganzinelli M, Maccauro M, Buzzoni R, Seregni E, de Braud F, Garassino MC. Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. *Tumor Biol*. 2016 July 15. (review)
87. Lo Russo G, Macerelli M, Platania M, Zilembo N, Vitali M, Signorelli D, **Proto C**, Ganzinelli M, Gallucci R, Agustoni F, Fasola G, de Braud F, Garassino MC. Small-cell lung cancer: clinical management and unmet needs. New perspectives for an old problem. *Current Drug Targets*, 2017, 18, 341-362 (review)
88. Pelosi G, Pellegrinelli A, Fabbri A, Tamborini E, Perrone F, Settanni G, Busico A, Piccioni B, Testi MA, Militti L, Maisonneuve P, Valeri B, Sonzogni A, **Proto C**, Garassino M, De Braud F, Pastorino U. Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules. *Virchows Arch* (2016) 468:651–662
89. Lo Russo G, Pusceddu S, **Proto C**, Lo Russo G, Signorelli D, Vitali M, Ganzinelli M, Gallucci R, Zilembo N, Platania M, Buzzoni R, de Braud F, Marina Garassino MC. Treatment of lung large cell neuroendocrine carcinoma. *Tumour Biol*, 2016. (review).
90. Pusceddu S, Lo Russo G, Macerelli M, **Proto C**, Vitali M, Signorelli D, Ganzinelli M, Scanagatta P, Duranti L, Trama A, Buzzoni R, Pelosi G, Pastorino U, de Braud F, Garassino MC. Diagnosis and management of typical and atypical lung carcinoids. *Crit Rev Oncol Hematol* 2016. (review)
91. Lo Russo G\*, **Proto C\***, Garassino MC. Afatinib in the treatment of squamous Non-Small Cell Lung Cancer: a new frontier or an old mistake? *TLCR*. 2016 Oct 28 (editorial) (*First name, equal contribute to the first author*).
92. Signorelli D, Macerelli M, **Proto C**, Vitali M, Cona MS, Agustoni F, Zilembo N, Platania M, Trama A, Gallucci R, Ganzinelli M, Pelosi G, Pastorino U, de Braud F, Garassino MC, Lo Russo G. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy? *Tumori* 2016;102(1):18-30.(review)
93. Barni S, Maiello E, Di Maio M, Ardizzoni A, Cappuzzo F, Maranzano E, Novello S,

Bennati C, Ori A, Rizzoli S, Crinò L; RIGHT-3 study group. (Collaborators: Barni S, Maiello E, Di Maio M, Crinò L, Ardizzoni A, Cappuzzo F, Maranzano E, Novello S, Barni S, Petrelli F, Raisi E, Frassoldati A, Santini A, Longo P, Botta M, Oletti MV, Biaggi G, Muzio A, Gattoni E, Giaretto L, Bertoldo E, Perroni D, Facilissimo I, Evangelisti L, Del Conte A, Ius A, Numico G, Cristofano A, Barè C, Ballardini P, Margutti G, Tiseo M, Camisa R, Rapacchi E, Bartolotti M, Cortinovis D, Gila MP, Grossi F, Donato C, Dal Bello MG, Rijavec E, Barletta G, Genova C, Diaz N, Sini C, Boni C, Zanelli F, Gnoni R, Stridi G, Magnani E, Gervasi E, Fanello S, Lonati V, Petrelli F, Cremonesi M, Del Conte G, Dicorato A, Caffo O, Murgia V, Veccia A, Giordano M, Gilardoni M, Luchena M, Vattermi E, Barbieri F, Marra L, Pettorelli E, Mazzocchi MG, Meriggi F, Spaggiari L, Solli P, Martoni AA, Melotti B, Esposti CD, Amadori D, Monti M, Milandri C, Rosti G, Bertolin M, McMahon L, Mauri M, Martelli O, Di Lieto M, Ricasoli M, Recchia F, Di Blasio A, Candeloro G, Baldini E, Pellegrini M, Coppi E, Cirigliano G, Tursi M, Iacobelli S, Irtelli L, Giampietro J, Tinari N, Cascinu S, Berardi R, Lucarelli A, Pierantoni C, Onofri A, Burattini M, Crinò L, Marchetti F, Chiari R, Bennati C, Di Costanzo F, Cecere F, Ranchicchio CP, Mazzoni F, Cristina L, Travagliato L, Rinaldi A, Bruno S, Adamo V, Franchina T, **Proto C**, Maiorino L, Musicò M, Ortu S, Putzu C, Galetta D, Catino A, Rizzi D, Palomba G, Capuano G, Bellocchio G, Nardi M, Giannicola R, Falzea A, Carteni G, Fiorentino R, Otero M, Planeta A, Giovanis P, Testore F, Ceste M, Dongiovanni D, Mencoboni M, Tonini G, Intagliata S, Potestà C, Maio M, Calabrò L, Annesi D, Bordonaro R, Longhitano L, Contu A, Contu M, Pazzola A, Lorusso V, Petrucelli L, Romano G, Gambino A, Agostara B, Savio G, Signorini A, Turrini M, De Signoribus G, Brugni M, Cappuzzo F, Lani E, Landi L, Minuti G, D'Incecco A, Palazzo S, Turano S, Biamonte R, Manfredi C, Iacono C, Licitra S, Ori A, Rizzoli S, Sala S, Sgarbi S, Simoni L, Trevisan F, Fiori G). Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study. *Lung Cancer*. 2015 Nov;90(2):234-42.

94. Ricciardi GR, **Proto C**, Ferraro G, Adamo V. Uncommon breast metastatic site and eribulin responsiveness in a heavily pretreated patient. *Future Oncol*. 2014 Dec;10(15):2417-22. (clinical case)
95. Franchina T, Adamo B, Ricciardi GR, Caristi N, Agostino RM, **Proto C**, Adamo V. Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: two case reports. *Cancer Biol Ther* 2012 May;13(7):472-6. (clinical case)

## ORAL PRESENTATIONS

- Yokohama, 30/10 – 01/11/24 Japan 14<sup>th</sup> International Thymic Malignancies Interest Group Annual Meeting. Focus on Thymic carcinoma – What is Different from Thymoma. Present options and future directions for Thymic Carcinoma
- Madrid, Spain 20-24/10/23, ESMO congress 2023 #LBA98 Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVANT phase II trial Proffered Paper Presentation
- Milano, 22-24/06/23 Italia, VII Convegno Nazionale della rete oncologica SIFACT. Oltre il modello mutazionale e l'oncologia di precisione: la medicina personalizzata. Keynote News from ASCO: la medicina personalizzata
- Roma, 16-19/11/22 Italia 41° Congresso della società italiana di farmacologia, il valore scientifico e l'uso appropriato del farmaco "The evolution of early stage non-small-cell lung cancer treatment and the new role of immunotherapy"
- Vienna, Austria 06-09/08/2022 WCLC 2022 Phase II Trial of Sunitinib in Patients with Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines – STYLE Trial (NCT03449173) (Minioral presentation)
- Milano, 07-08/09/2020 The Best of the year in lung cancer-Virtual conference
- Barcelona, 07-10/09/19 WCLC 2019 A plasma microRNA classifier as biomarker of primary and secondary resistance in PD-L1 $\geq$ 50% NSCLC treated with immunotherapy
- Milano, 17/12/2018 Expert Strategies. How to use immunotherapy in advanced lung cancer.
- San Benedetto del Tronto, 10/11/18 Marcangolo 2018, "Prima o poi dobbiamo tutti affrontare la scelta tra ciò che è giusto e ciò che è facile..."
- Palermo, 02/10/2018 Salute donna Onlus- Salute Uomo Tumore al polmone e Tumori della testa e del collo. News in immuno-oncologia: overview degli studi clinici e prospettive terapeutiche nel tumore polmonare
- Milano, 28-29/06/2018 MASTERLUNG
- Bergamo, 04-05/05/18 Le nuove sfide professionali nell'immunoterapia dei tumori polmonari
- Messina, 12-13/10/2017 2nd Sicilian Oncologist day: linee guida AIOM, appropriatezza e medicina di precisione
- Siena, 05-07/10/2017 XV NIBIT Meeting Anti-PD-1 mAbs for the treatment of NSCLC patients
- Milano, 09/02/2016. Tutto quello che avresti voluto chiedere.
- Catania, 1-2/04/2016. Focus sul carcinoma del polmone: assistenza e ricerca
- Milano, 19/4/2016. Fondazione IRCCS Istituto Nazionale dei Tumori. Insieme per le neoplasie toraciche.... Tra sogno e realtà.
- Messina 14/04/2013 SCCHN: decidere, sostenere, curare insieme.
- Messina, Hospital meetings

La sottoscritta inoltre, avvalendosi della facoltà concessa dall'art. 46 D.P.R. 28/12/2000 n. 445, consapevole delle responsabilità penali previste dall'art. 76 del citato D.P.R. per le ipotesi di falsità in atti e di dichiarazioni mendaci, sotto la propria responsabilità DICHIARA: che quanto qui sopra riportato corrisponde a verità

La sottoscritta acconsente e autorizza al trattamento dei dati coperti e tutelati dalla legge sulla privacy e dal GDPR – Regolamento generale sulla protezione dati in vigore in tutti i paesi dell'Unione Europea dal 25 Maggio 2018

**Date 10/04/2025**

**Name** Proto Claudia

FIRMA 